JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267033

Human KDM7A (JHDM1D) knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

Human KDM7A (JHDM1D) knockout A549 cell line available to order. Recommended control: Human wild-type A549 cell line (ab255450).

View Alternative Names

JmjC domain-containing histone demethylation protein 1D, KDM7_HUMAN, Lysine-specific demethylase 7, jmjc containing protein, jumonji containing protein, kiaa1718

3 Images
Sanger Sequencing - Human KDM7A (JHDM1D) knockout A549 cell line (AB267033)
  • Sanger seq

Unknown

Sanger Sequencing - Human KDM7A (JHDM1D) knockout A549 cell line (AB267033)

Allele-3 : 1 bp deletion in exon 5.

Sanger Sequencing - Human KDM7A (JHDM1D) knockout A549 cell line (AB267033)
  • Sanger seq

Unknown

Sanger Sequencing - Human KDM7A (JHDM1D) knockout A549 cell line (AB267033)

Allele-2 : 7 bp deletion in exon 5.

Sanger Sequencing - Human KDM7A (JHDM1D) knockout A549 cell line (AB267033)
  • Sanger seq

Unknown

Sanger Sequencing - Human KDM7A (JHDM1D) knockout A549 cell line (AB267033)

Allele-1 : 8 bp deletion in exon5

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 5 and 7 bp deletion in exon 5 and 8 bp deletion in exon 5

Disease

Carcinoma

Product details

Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267033-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267033 Human KDM7A (JHDM1D) knockout A549 cell line", "number":"AB267033-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267033-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267033 Human KDM7A (JHDM1D) knockout A549 cell line", "number":"AB267033-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
KDM7A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

JHDM1D also known as KDM7A is a histone demethylase enzyme involved in the removal of methyl groups from di- and trimethylated lysine residues on histone tails particularly at H3K9 and H3K27. This action impacts gene expression by altering chromatin structure making it an important player in regulating transcriptional activities. The target has a molecular mass of approximately 129 kDa. JHDM1D is widely expressed in various tissues with notably high expression levels in the brain and testis indicating its importance in these organs.
Biological function summary

JHDM1D functions as part of a larger protein complex that regulates chromatin remodeling and gene expression. It plays a significant role in epigenetic modification processes influencing cell differentiation and development through its demethylation activity. Such capabilities affect cellular proliferation and lineage specification and may impact immune responses and neurological functions.

Pathways

Epigenetic regulation and chromatin remodeling see direct involvement from JHDM1D through pathways including the histone modification pathway and Wnt signaling pathway. In these pathways JHDM1D interacts with related proteins like EZH2 which also takes part in chromatin modifications and transcriptional control. This interplay highlights the importance of JHDM1D in fine-tuning gene expression.

Altered JHDM1D function relates to cancer progression and multiple neurological disorders. Dysregulation of this protein may contribute to abnormal cell growth and development as seen in certain cancers. Additionally its interactions with proteins like p53 suggest a potential role in tumor suppression pathways. In neurological disorders JHDM1D's impact on brain-specific gene expression may underline deficits seen in conditions like autism spectrum disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com